ChloroquineV1, Istex, Corpus, bibRecord, 001436

Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome

Identifieur interne : 001436 ( Istex/Corpus ); précédent : 001435; suivant : 001437

Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome

Auteurs : J-E Gottenberg ; M. Busson ; J. Cohen-Solal ; F. Lavie ; K. Abbed ; R P Kimberly ; J. Sibilia ; X. Mariette

Source :

Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2005-07.

RBID : ISTEX:09EF1A5FE6EEE42F7CC060AD8734A806E9491908

English descriptors

Abstract

Background: In primary Sjögren’s syndrome (pSS), extraglandular involvement might result from more intense stimulation of autoreactive B cells. Thus markers of B cell activation could be useful in the clinical assessment of this disease. Objective: To investigate the association of serum B lymphocyte stimulator (BLyS) and β2 microglobulin with autoantibody production and extraglandular involvement in pSS. Methods: Serum concentrations of BLyS and β2 microglobulin were analysed in 177 patients with pSS according to the American–European consensus group criteria. Serum β2 microglobulin was determined serially in 25 patients. Results: Autoantibody secretion (presence of anti-SSA antibody alone or of both anti-SSA and anti-SSB) was associated with increased serum BLyS and β2 microglobulin. No correlation was found between BLyS and β2 microglobulin levels (p = 0.36). Serum concentrations of β2 microglobulin and C reactive protein and positive anti-SSB antibody results were associated with extraglandular involvement on univariate analysis (p<10−4, p = 0.003, and p = 0.004, respectively). Serum β2 microglobulin was also significantly increased in patients with extraglandular involvement without autoantibodies (mean (SD): 1.75 (0.7) v 1.39 (0.5) mg/l, p = 0.039). Multivariate analysis showed that extraglandular involvement was associated only with increased serum β2 microglobulin (p = 0.035, odds ratio = 2.78 (95% confidence interval, 1.07 to 7.22)). Among the 25 patients who had serial determinations of serum β2 microglobulin, the concentrations were increased in all those with disease flare and decreased in three following treatment. Serum BLyS, gamma globulin, IgG, and rheumatoid factor levels were not associated with features of systemic involvement. Conclusions: Serum β2 microglobulin and BLyS reflect B cell activation in different ways in pSS. Serum β2 microglobulin assessment could be helpful as an activity marker in pSS.

Url:

https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/fulltext.pdf

DOI: 10.1136/ard.2004.030643

Links to Exploration step

ISTEX:09EF1A5FE6EEE42F7CC060AD8734A806E9491908

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</title>
<author><name sortKey="Gottenberg, J E" sort="Gottenberg, J E" uniqKey="Gottenberg J" first="J-E" last="Gottenberg">J-E Gottenberg</name>
<affiliation><mods:affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Busson, M" sort="Busson, M" uniqKey="Busson M" first="M" last="Busson">M. Busson</name>
<affiliation><mods:affiliation>INSERM U396 et Immunologie et Histocompatibilité, Hôpital Saint-Louis (AP-HP), Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cohen Solal, J" sort="Cohen Solal, J" uniqKey="Cohen Solal J" first="J" last="Cohen-Solal">J. Cohen-Solal</name>
<affiliation><mods:affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lavie, F" sort="Lavie, F" uniqKey="Lavie F" first="F" last="Lavie">F. Lavie</name>
<affiliation><mods:affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Abbed, K" sort="Abbed, K" uniqKey="Abbed K" first="K" last="Abbed">K. Abbed</name>
<affiliation><mods:affiliation>Immunologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kimberly, R P" sort="Kimberly, R P" uniqKey="Kimberly R" first="R P" last="Kimberly">R P Kimberly</name>
<affiliation><mods:affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sibilia, J" sort="Sibilia, J" uniqKey="Sibilia J" first="J" last="Sibilia">J. Sibilia</name>
<affiliation><mods:affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mariette, X" sort="Mariette, X" uniqKey="Mariette X" first="X" last="Mariette">X. Mariette</name>
<affiliation><mods:affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:09EF1A5FE6EEE42F7CC060AD8734A806E9491908</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1136/ard.2004.030643</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001436</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001436</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</title>
<author><name sortKey="Gottenberg, J E" sort="Gottenberg, J E" uniqKey="Gottenberg J" first="J-E" last="Gottenberg">J-E Gottenberg</name>
<affiliation><mods:affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Busson, M" sort="Busson, M" uniqKey="Busson M" first="M" last="Busson">M. Busson</name>
<affiliation><mods:affiliation>INSERM U396 et Immunologie et Histocompatibilité, Hôpital Saint-Louis (AP-HP), Paris, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Cohen Solal, J" sort="Cohen Solal, J" uniqKey="Cohen Solal J" first="J" last="Cohen-Solal">J. Cohen-Solal</name>
<affiliation><mods:affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Lavie, F" sort="Lavie, F" uniqKey="Lavie F" first="F" last="Lavie">F. Lavie</name>
<affiliation><mods:affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Abbed, K" sort="Abbed, K" uniqKey="Abbed K" first="K" last="Abbed">K. Abbed</name>
<affiliation><mods:affiliation>Immunologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Kimberly, R P" sort="Kimberly, R P" uniqKey="Kimberly R" first="R P" last="Kimberly">R P Kimberly</name>
<affiliation><mods:affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Sibilia, J" sort="Sibilia, J" uniqKey="Sibilia J" first="J" last="Sibilia">J. Sibilia</name>
<affiliation><mods:affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Mariette, X" sort="Mariette, X" uniqKey="Mariette X" first="X" last="Mariette">X. Mariette</name>
<affiliation><mods:affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2005-07">2005-07</date>
<biblScope unit="volume">64</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="1050">1050</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>BLyS</term>
<term>BLyS, B lymphocyte stimulator</term>
<term>PSS, primary Sjögren’s syndrome</term>
<term>SJC, swollen joint count</term>
<term>SSA/SSB, Sjögren’s syndrome antigen A or B</term>
<term>anti-SSA/SSB</term>
<term>primary Sjögren’s syndrome</term>
<term>β2 microglobulin</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Arthritis rheum</term>
<term>Autoantibody</term>
<term>Autoantibody production</term>
<term>Autoantibody secretion</term>
<term>Bicetre</term>
<term>Blys</term>
<term>Blys levels</term>
<term>Bronchiolar involvement</term>
<term>Cell activation</term>
<term>Disease activity</term>
<term>Erythrocyte sedimentation rate</term>
<term>Extraglandular</term>
<term>Extraglandular involvement</term>
<term>Gamma globulin</term>
<term>Hopital</term>
<term>Hydroxychloroquine</term>
<term>Hydroxychloroquine treatment</term>
<term>Kremlin bicetre</term>
<term>Lymphocyte</term>
<term>Lymphocyte stimulator</term>
<term>Lymphoma</term>
<term>Major histocompatibility</term>
<term>Microglobulin</term>
<term>Microglobulin concentration</term>
<term>Microglobulin level</term>
<term>Microglobulin levels</term>
<term>Microglobulin value</term>
<term>Multivariate</term>
<term>Multivariate analysis</term>
<term>Neurological involvement</term>
<term>Positive results</term>
<term>Primary syndrome</term>
<term>Reactive</term>
<term>Reactive protein</term>
<term>Reactive protein level</term>
<term>Rheum</term>
<term>Rheumatoid</term>
<term>Rheumatoid factor</term>
<term>Serial determinations</term>
<term>Serum</term>
<term>Serum blys</term>
<term>Serum concentrations</term>
<term>Stimulator</term>
<term>Syndrome</term>
<term>Systemic involvement</term>
<term>Systemic lupus erythematosus</term>
<term>Univariate</term>
<term>Univariate analysis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: In primary Sjögren’s syndrome (pSS), extraglandular involvement might result from more intense stimulation of autoreactive B cells. Thus markers of B cell activation could be useful in the clinical assessment of this disease. Objective: To investigate the association of serum B lymphocyte stimulator (BLyS) and β2 microglobulin with autoantibody production and extraglandular involvement in pSS. Methods: Serum concentrations of BLyS and β2 microglobulin were analysed in 177 patients with pSS according to the American–European consensus group criteria. Serum β2 microglobulin was determined serially in 25 patients. Results: Autoantibody secretion (presence of anti-SSA antibody alone or of both anti-SSA and anti-SSB) was associated with increased serum BLyS and β2 microglobulin. No correlation was found between BLyS and β2 microglobulin levels (p = 0.36). Serum concentrations of β2 microglobulin and C reactive protein and positive anti-SSB antibody results were associated with extraglandular involvement on univariate analysis (p<10−4, p = 0.003, and p = 0.004, respectively). Serum β2 microglobulin was also significantly increased in patients with extraglandular involvement without autoantibodies (mean (SD): 1.75 (0.7) v 1.39 (0.5) mg/l, p = 0.039). Multivariate analysis showed that extraglandular involvement was associated only with increased serum β2 microglobulin (p = 0.035, odds ratio = 2.78 (95% confidence interval, 1.07 to 7.22)). Among the 25 patients who had serial determinations of serum β2 microglobulin, the concentrations were increased in all those with disease flare and decreased in three following treatment. Serum BLyS, gamma globulin, IgG, and rheumatoid factor levels were not associated with features of systemic involvement. Conclusions: Serum β2 microglobulin and BLyS reflect B cell activation in different ways in pSS. Serum β2 microglobulin assessment could be helpful as an activity marker in pSS.</div>
</front>
</TEI>
<istex><corpusName>bmj</corpusName>
<keywords><teeft><json:string>microglobulin</json:string>
<json:string>blys</json:string>
<json:string>extraglandular</json:string>
<json:string>extraglandular involvement</json:string>
<json:string>autoantibody</json:string>
<json:string>primary syndrome</json:string>
<json:string>serum blys</json:string>
<json:string>microglobulin level</json:string>
<json:string>rheumatoid</json:string>
<json:string>stimulator</json:string>
<json:string>lymphocyte</json:string>
<json:string>cell activation</json:string>
<json:string>syndrome</json:string>
<json:string>reactive</json:string>
<json:string>lymphocyte stimulator</json:string>
<json:string>bicetre</json:string>
<json:string>multivariate analysis</json:string>
<json:string>multivariate</json:string>
<json:string>arthritis rheum</json:string>
<json:string>univariate</json:string>
<json:string>gamma globulin</json:string>
<json:string>rheumatoid factor</json:string>
<json:string>hydroxychloroquine</json:string>
<json:string>hopital</json:string>
<json:string>rheum</json:string>
<json:string>univariate analysis</json:string>
<json:string>systemic involvement</json:string>
<json:string>reactive protein</json:string>
<json:string>lymphoma</json:string>
<json:string>autoantibody production</json:string>
<json:string>positive results</json:string>
<json:string>disease activity</json:string>
<json:string>autoantibody secretion</json:string>
<json:string>kremlin bicetre</json:string>
<json:string>microglobulin value</json:string>
<json:string>microglobulin levels</json:string>
<json:string>erythrocyte sedimentation rate</json:string>
<json:string>serum</json:string>
<json:string>bronchiolar involvement</json:string>
<json:string>major histocompatibility</json:string>
<json:string>neurological involvement</json:string>
<json:string>microglobulin concentration</json:string>
<json:string>blys levels</json:string>
<json:string>reactive protein level</json:string>
<json:string>serial determinations</json:string>
<json:string>hydroxychloroquine treatment</json:string>
<json:string>serum concentrations</json:string>
<json:string>systemic lupus erythematosus</json:string>
</teeft>
</keywords>
<author><json:item><name>J-E Gottenberg</name>
<affiliations><json:string>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</json:string>
</affiliations>
</json:item>
<json:item><name>M Busson</name>
<affiliations><json:string>INSERM U396 et Immunologie et Histocompatibilité, Hôpital Saint-Louis (AP-HP), Paris, France</json:string>
</affiliations>
</json:item>
<json:item><name>J Cohen-Solal</name>
<affiliations><json:string>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</json:string>
</affiliations>
</json:item>
<json:item><name>F Lavie</name>
<affiliations><json:string>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</json:string>
</affiliations>
</json:item>
<json:item><name>K Abbed</name>
<affiliations><json:string>Immunologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre</json:string>
</affiliations>
</json:item>
<json:item><name>R P Kimberly</name>
<affiliations><json:string>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA</json:string>
</affiliations>
</json:item>
<json:item><name>J Sibilia</name>
<affiliations><json:string>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</json:string>
</affiliations>
</json:item>
<json:item><name>X Mariette</name>
<affiliations><json:string>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>BLyS, B lymphocyte stimulator</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>PSS, primary Sjögren’s syndrome</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>SJC, swollen joint count</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>SSA/SSB, Sjögren’s syndrome antigen A or B</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>β2 microglobulin</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>BLyS</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>anti-SSA/SSB</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>primary Sjögren’s syndrome</value>
</json:item>
</subject>
<arkIstex>ark:/67375/NVC-58CLR79L-G</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>other</json:string>
</originalGenre>
<abstract>Background: In primary Sjögren’s syndrome (pSS), extraglandular involvement might result from more intense stimulation of autoreactive B cells. Thus markers of B cell activation could be useful in the clinical assessment of this disease. Objective: To investigate the association of serum B lymphocyte stimulator (BLyS) and β2 microglobulin with autoantibody production and extraglandular involvement in pSS. Methods: Serum concentrations of BLyS and β2 microglobulin were analysed in 177 patients with pSS according to the American–European consensus group criteria. Serum β2 microglobulin was determined serially in 25 patients. Results: Autoantibody secretion (presence of anti-SSA antibody alone or of both anti-SSA and anti-SSB) was associated with increased serum BLyS and β2 microglobulin. No correlation was found between BLyS and β2 microglobulin levels (p = 0.36). Serum concentrations of β2 microglobulin and C reactive protein and positive anti-SSB antibody results were associated with extraglandular involvement on univariate analysis (p>10−4, p = 0.003, and p = 0.004, respectively). Serum β2 microglobulin was also significantly increased in patients with extraglandular involvement without autoantibodies (mean (SD): 1.75 (0.7) v 1.39 (0.5) mg/l, p = 0.039). Multivariate analysis showed that extraglandular involvement was associated only with increased serum β2 microglobulin (p = 0.035, odds ratio = 2.78 (95% confidence interval, 1.07 to 7.22)). Among the 25 patients who had serial determinations of serum β2 microglobulin, the concentrations were increased in all those with disease flare and decreased in three following treatment. Serum BLyS, gamma globulin, IgG, and rheumatoid factor levels were not associated with features of systemic involvement. Conclusions: Serum β2 microglobulin and BLyS reflect B cell activation in different ways in pSS. Serum β2 microglobulin assessment could be helpful as an activity marker in pSS.</abstract>
<qualityIndicators><score>10</score>
<pdfWordCount>5034</pdfWordCount>
<pdfCharCount>34355</pdfCharCount>
<pdfVersion>1.3</pdfVersion>
<pdfPageCount>6</pdfPageCount>
<pdfPageSize>612 x 792 pts (letter)</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractWordCount>267</abstractWordCount>
<abstractCharCount>1954</abstractCharCount>
<keywordCount>8</keywordCount>
</qualityIndicators>
<title>Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</title>
<pmid><json:string>15640273</json:string>
</pmid>
<genre><json:string>other</json:string>
</genre>
<host><title>Annals of the Rheumatic Diseases</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>0003-4967</json:string>
</issn>
<eissn><json:string>1468-2060</json:string>
</eissn>
<volume>64</volume>
<issue>7</issue>
<pages><first>1050</first>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Immunology (including allergy)</value>
</json:item>
</subject>
</host>
<namedEntities><unitex><date><json:string>2005-01-07</json:string>
</date>
<geogName></geogName>
<orgName><json:string>University of Alabama</json:string>
<json:string>Division of Clinical Immunology</json:string>
<json:string>Southern Biotechnology, Birmingham</json:string>
<json:string>Bicetre Hospital, Le Kremlin Bicetre, France</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>Blood</json:string>
<json:string>B. Serum</json:string>
<json:string>Varelisa</json:string>
<json:string>Of</json:string>
<json:string>Xavier Mariette</json:string>
</persName>
<placeName><json:string>Birmingham</json:string>
<json:string>Paris</json:string>
<json:string>Germany</json:string>
<json:string>Sacramento</json:string>
<json:string>American</json:string>
<json:string>Strasbourg</json:string>
<json:string>France</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl></ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/NVC-58CLR79L-G</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - rheumatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - arthritis & rheumatology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Life Sciences</json:string>
<json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string>
<json:string>3 - General Biochemistry, Genetics and Molecular Biology</json:string>
<json:string>1 - Life Sciences</json:string>
<json:string>2 - Immunology and Microbiology</json:string>
<json:string>3 - Immunology</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Immunology and Allergy</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Rheumatology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
<json:string>4 - sarcoidoses. granulomatoses d'etiologie indeterminee. maladies du tissu conjonctif. maladies du tissu elastique. vascularites</json:string>
</inist>
</categories>
<publicationDate>2005</publicationDate>
<copyrightDate>2005</copyrightDate>
<doi><json:string>10.1136/ard.2004.030643</json:string>
</doi>
<id>09EF1A5FE6EEE42F7CC060AD8734A806E9491908</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<availability><licence><p>Copyright 2005 by Annals of the Rheumatic Diseases</p>
</licence>
<p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p>
</availability>
<date>2005-01-07</date>
</publicationStmt>
<notesStmt><note type="other" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</note>
<note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
<note>Correspondence to:  Professor Xavier Mariette  Service de Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France; xavier.mariette@bct.ap-hop-paris.fr</note>
</notesStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</title>
<author xml:id="author-0000"><persName><forename type="first">J-E</forename>
<surname>Gottenberg</surname>
</persName>
<affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">M</forename>
<surname>Busson</surname>
</persName>
<affiliation>INSERM U396 et Immunologie et Histocompatibilité, Hôpital Saint-Louis (AP-HP), Paris, France</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">J</forename>
<surname>Cohen-Solal</surname>
</persName>
<affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">F</forename>
<surname>Lavie</surname>
</persName>
<affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">K</forename>
<surname>Abbed</surname>
</persName>
<affiliation>Immunologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">R P</forename>
<surname>Kimberly</surname>
</persName>
<affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA</affiliation>
</author>
<author xml:id="author-0006"><persName><forename type="first">J</forename>
<surname>Sibilia</surname>
</persName>
<affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</affiliation>
</author>
<author xml:id="author-0007"><persName><forename type="first">X</forename>
<surname>Mariette</surname>
</persName>
<affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</affiliation>
</author>
<idno type="istex">09EF1A5FE6EEE42F7CC060AD8734A806E9491908</idno>
<idno type="ark">ark:/67375/NVC-58CLR79L-G</idno>
<idno type="DOI">10.1136/ard.2004.030643</idno>
<idno type="href">annrheumdis-64-1050.pdf</idno>
<idno type="PMID">15640273</idno>
<idno type="local">0641050</idno>
</analytic>
<monogr><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="pISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<idno type="PublisherID-hwp">annrheumdis</idno>
<idno type="PublisherID-nlm-ta">Ann Rheum Dis</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2005-07"></date>
<biblScope unit="volume">64</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="1050">1050</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>2005-01-07</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Background: In primary Sjögren’s syndrome (pSS), extraglandular involvement might result from more intense stimulation of autoreactive B cells. Thus markers of B cell activation could be useful in the clinical assessment of this disease. Objective: To investigate the association of serum B lymphocyte stimulator (BLyS) and β2 microglobulin with autoantibody production and extraglandular involvement in pSS. Methods: Serum concentrations of BLyS and β2 microglobulin were analysed in 177 patients with pSS according to the American–European consensus group criteria. Serum β2 microglobulin was determined serially in 25 patients. Results: Autoantibody secretion (presence of anti-SSA antibody alone or of both anti-SSA and anti-SSB) was associated with increased serum BLyS and β2 microglobulin. No correlation was found between BLyS and β2 microglobulin levels (p = 0.36). Serum concentrations of β2 microglobulin and C reactive protein and positive anti-SSB antibody results were associated with extraglandular involvement on univariate analysis (p<10−4, p = 0.003, and p = 0.004, respectively). Serum β2 microglobulin was also significantly increased in patients with extraglandular involvement without autoantibodies (mean (SD): 1.75 (0.7) v 1.39 (0.5) mg/l, p = 0.039). Multivariate analysis showed that extraglandular involvement was associated only with increased serum β2 microglobulin (p = 0.035, odds ratio = 2.78 (95% confidence interval, 1.07 to 7.22)). Among the 25 patients who had serial determinations of serum β2 microglobulin, the concentrations were increased in all those with disease flare and decreased in three following treatment. Serum BLyS, gamma globulin, IgG, and rheumatoid factor levels were not associated with features of systemic involvement. Conclusions: Serum β2 microglobulin and BLyS reflect B cell activation in different ways in pSS. Serum β2 microglobulin assessment could be helpful as an activity marker in pSS.</p>
</abstract>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>ABR</head>
<item><term>BLyS, B lymphocyte stimulator</term>
</item>
<item><term>PSS, primary Sjögren’s syndrome</term>
</item>
<item><term>SJC, swollen joint count</term>
</item>
<item><term>SSA/SSB, Sjögren’s syndrome antigen A or B</term>
</item>
</list>
</keywords>
</textClass>
<textClass xml:lang="en"><keywords scheme="keyword"><list><head>KWD</head>
<item><term>β2 microglobulin</term>
</item>
<item><term>BLyS</term>
</item>
<item><term>anti-SSA/SSB</term>
</item>
<item><term>primary Sjögren’s syndrome</term>
</item>
</list>
</keywords>
</textClass>
<textClass><keywords scheme="Journal Subject"><list><head>hwp-journal-coll</head>
<item><term>Immunology (including allergy)</term>
</item>
</list>
</keywords>
</textClass>
</profileDesc>
<revisionDesc><change when="2005-01-07">Created</change>
<change when="2005-07">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType>
<istex:document><article xml:lang="en" article-type="other"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id>
<journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id>
<journal-title>Annals of the Rheumatic Diseases</journal-title>
<abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title>
<issn pub-type="ppub">0003-4967</issn>
<issn pub-type="epub">1468-2060</issn>
<publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="other">0641050</article-id>
<article-id pub-id-type="doi">10.1136/ard.2004.030643</article-id>
<article-id pub-id-type="other">annrheumdis;64/7/1050</article-id>
<article-id pub-id-type="other">annrheumdis;ard.2004.030643</article-id>
<article-id pub-id-type="pmid">15640273</article-id>
<article-id pub-id-type="other">1050</article-id>
<article-id pub-id-type="other">ard.2004.030643</article-id>
<article-categories><subj-group subj-group-type="heading"><subject content-type="original">Extended reports</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll"><subject>Immunology (including allergy)</subject>
</subj-group>
</article-categories>
<title-group><article-title>Correlation of serum B lymphocyte stimulator and β<sub>2</sub>
 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</article-title>
</title-group>
<contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gottenberg</surname>
<given-names>J-E</given-names>
</name>
<xref rid="AFF1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Busson</surname>
<given-names>M</given-names>
</name>
<xref rid="AFF2">2</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cohen-Solal</surname>
<given-names>J</given-names>
</name>
<xref rid="AFF3">3</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lavie</surname>
<given-names>F</given-names>
</name>
<xref rid="AFF1">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abbed</surname>
<given-names>K</given-names>
</name>
<xref rid="AFF4">4</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kimberly</surname>
<given-names>R P</given-names>
</name>
<xref rid="AFF5">5</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sibilia</surname>
<given-names>J</given-names>
</name>
<xref rid="AFF3">3</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mariette</surname>
<given-names>X</given-names>
</name>
<xref rid="AFF1">1</xref>
</contrib>
<aff id="AFF1"><label>1</label>
Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</aff>
<aff id="AFF2"><label>2</label>
INSERM U396 et Immunologie et Histocompatibilité, Hôpital Saint-Louis (AP-HP), Paris, France</aff>
<aff id="AFF3"><label>3</label>
Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</aff>
<aff id="AFF4"><label>4</label>
Immunologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre</aff>
<aff id="AFF5"><label>5</label>
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA</aff>
</contrib-group>
<author-notes><corresp>Correspondence to:  Professor Xavier Mariette  Service de Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France; <ext-link xlink:href="xavier.mariettebct.ap-hop-paris.fr" ext-link-type="email" xlink:type="simple">xavier.mariette@bct.ap-hop-paris.fr</ext-link>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>7</month>
<year>2005</year>
</pub-date>
<pub-date pub-type="epub"><day>7</day>
<month>1</month>
<year>2005</year>
</pub-date>
<volume>64</volume>
<volume-id pub-id-type="other">64</volume-id>
<volume-id pub-id-type="other">64</volume-id>
<issue>7</issue>
<issue-id pub-id-type="other">annrheumdis;64/7</issue-id>
<issue-id pub-id-type="other">7</issue-id>
<issue-id pub-id-type="other">64/7</issue-id>
<fpage>1050</fpage>
<history><date date-type="accepted"><day>16</day>
<month>11</month>
<year>2004</year>
</date>
</history>
<permissions><copyright-statement>Copyright 2005 by Annals of the Rheumatic Diseases</copyright-statement>
<copyright-year>2005</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-64-1050.pdf"></self-uri>
<abstract xml:lang="en"><p><bold>Background:</bold>
 In primary Sjögren’s syndrome (pSS), extraglandular involvement might result from more intense stimulation of autoreactive B cells. Thus markers of B cell activation could be useful in the clinical assessment of this disease.</p>
<p><bold>Objective:</bold>
 To investigate the association of serum B lymphocyte stimulator (BLyS) and β<sub>2</sub>
 microglobulin with autoantibody production and extraglandular involvement in pSS.</p>
<p><bold>Methods:</bold>
 Serum concentrations of BLyS and β<sub>2</sub>
 microglobulin were analysed in 177 patients with pSS according to the American–European consensus group criteria. Serum β<sub>2</sub>
 microglobulin was determined serially in 25 patients.</p>
<p><bold>Results:</bold>
 Autoantibody secretion (presence of anti-SSA antibody alone or of both anti-SSA and anti-SSB) was associated with increased serum BLyS and β<sub>2</sub>
 microglobulin. No correlation was found between BLyS and β<sub>2</sub>
 microglobulin levels (p = 0.36). Serum concentrations of β<sub>2</sub>
 microglobulin and C reactive protein and positive anti-SSB antibody results were associated with extraglandular involvement on univariate analysis (p<10<sup>−4</sup>
, p = 0.003, and p = 0.004, respectively). Serum β<sub>2</sub>
 microglobulin was also significantly increased in patients with extraglandular involvement without autoantibodies (mean (SD): 1.75 (0.7) <italic>v</italic>
 1.39 (0.5) mg/l, p = 0.039). Multivariate analysis showed that extraglandular involvement was associated only with increased serum β<sub>2</sub>
 microglobulin (p = 0.035, odds ratio = 2.78 (95% confidence interval, 1.07 to 7.22)). Among the 25 patients who had serial determinations of serum β<sub>2</sub>
 microglobulin, the concentrations were increased in all those with disease flare and decreased in three following treatment. Serum BLyS, gamma globulin, IgG, and rheumatoid factor levels were not associated with features of systemic involvement.</p>
<p><bold>Conclusions:</bold>
 Serum β<sub>2</sub>
 microglobulin and BLyS reflect B cell activation in different ways in pSS. Serum β<sub>2</sub>
 microglobulin assessment could be helpful as an activity marker in pSS.</p>
</abstract>
<kwd-group kwd-group-type="ABR" xml:lang="en"><kwd>BLyS, B lymphocyte stimulator</kwd>
<kwd>PSS, primary Sjögren’s syndrome</kwd>
<kwd>SJC, swollen joint count</kwd>
<kwd>SSA/SSB, Sjögren’s syndrome antigen A or B</kwd>
</kwd-group>
<kwd-group kwd-group-type="KWD" xml:lang="en"><kwd>β2 microglobulin</kwd>
<kwd>BLyS</kwd>
<kwd>anti-SSA/SSB</kwd>
<kwd>primary Sjögren’s syndrome</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</title>
</titleInfo>
<titleInfo type="alternative" lang="en" contentType="CDATA"><title>Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome</title>
</titleInfo>
<name type="personal"><namePart type="given">J-E</namePart>
<namePart type="family">Gottenberg</namePart>
<affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Busson</namePart>
<affiliation>INSERM U396 et Immunologie et Histocompatibilité, Hôpital Saint-Louis (AP-HP), Paris, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J</namePart>
<namePart type="family">Cohen-Solal</namePart>
<affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">F</namePart>
<namePart type="family">Lavie</namePart>
<affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">K</namePart>
<namePart type="family">Abbed</namePart>
<affiliation>Immunologie, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">R P</namePart>
<namePart type="family">Kimberly</namePart>
<affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J</namePart>
<namePart type="family">Sibilia</namePart>
<affiliation>Rhumatologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">X</namePart>
<namePart type="family">Mariette</namePart>
<affiliation>Rhumatologie, INSERM EMI 109, Bicêtre Hospital, Le Kremlin Bicêtre, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="other" displayLabel="other" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre>
<originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<dateIssued encoding="w3cdtf">2005-07</dateIssued>
<dateCreated encoding="w3cdtf">2005-01-07</dateCreated>
<copyrightDate encoding="w3cdtf">2005</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<abstract lang="en">Background: In primary Sjögren’s syndrome (pSS), extraglandular involvement might result from more intense stimulation of autoreactive B cells. Thus markers of B cell activation could be useful in the clinical assessment of this disease. Objective: To investigate the association of serum B lymphocyte stimulator (BLyS) and β2 microglobulin with autoantibody production and extraglandular involvement in pSS. Methods: Serum concentrations of BLyS and β2 microglobulin were analysed in 177 patients with pSS according to the American–European consensus group criteria. Serum β2 microglobulin was determined serially in 25 patients. Results: Autoantibody secretion (presence of anti-SSA antibody alone or of both anti-SSA and anti-SSB) was associated with increased serum BLyS and β2 microglobulin. No correlation was found between BLyS and β2 microglobulin levels (p = 0.36). Serum concentrations of β2 microglobulin and C reactive protein and positive anti-SSB antibody results were associated with extraglandular involvement on univariate analysis (p<10−4, p = 0.003, and p = 0.004, respectively). Serum β2 microglobulin was also significantly increased in patients with extraglandular involvement without autoantibodies (mean (SD): 1.75 (0.7) v 1.39 (0.5) mg/l, p = 0.039). Multivariate analysis showed that extraglandular involvement was associated only with increased serum β2 microglobulin (p = 0.035, odds ratio = 2.78 (95% confidence interval, 1.07 to 7.22)). Among the 25 patients who had serial determinations of serum β2 microglobulin, the concentrations were increased in all those with disease flare and decreased in three following treatment. Serum BLyS, gamma globulin, IgG, and rheumatoid factor levels were not associated with features of systemic involvement. Conclusions: Serum β2 microglobulin and BLyS reflect B cell activation in different ways in pSS. Serum β2 microglobulin assessment could be helpful as an activity marker in pSS.</abstract>
<note type="author-notes">Correspondence to:  Professor Xavier Mariette  Service de Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France; xavier.mariette@bct.ap-hop-paris.fr</note>
<subject lang="en"><genre>ABR</genre>
<topic>BLyS, B lymphocyte stimulator</topic>
<topic>PSS, primary Sjögren’s syndrome</topic>
<topic>SJC, swollen joint count</topic>
<topic>SSA/SSB, Sjögren’s syndrome antigen A or B</topic>
</subject>
<subject lang="en"><genre>KWD</genre>
<topic>β2 microglobulin</topic>
<topic>BLyS</topic>
<topic>anti-SSA/SSB</topic>
<topic>primary Sjögren’s syndrome</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Ann Rheum Dis</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<subject><genre>hwp-journal-coll</genre>
<topic>Immunology (including allergy)</topic>
</subject>
<identifier type="ISSN">0003-4967</identifier>
<identifier type="eISSN">1468-2060</identifier>
<identifier type="PublisherID-hwp">annrheumdis</identifier>
<identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>64</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>7</number>
</detail>
<extent unit="pages"><start>1050</start>
</extent>
</part>
</relatedItem>
<identifier type="istex">09EF1A5FE6EEE42F7CC060AD8734A806E9491908</identifier>
<identifier type="ark">ark:/67375/NVC-58CLR79L-G</identifier>
<identifier type="DOI">10.1136/ard.2004.030643</identifier>
<identifier type="href">annrheumdis-64-1050.pdf</identifier>
<identifier type="PMID">15640273</identifier>
<identifier type="local">0641050</identifier>
<accessCondition type="use and reproduction" contentType="copyright">Copyright 2005 by Annals of the Rheumatic Diseases</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource>
<recordOrigin>Copyright 2005 by Annals of the Rheumatic Diseases</recordOrigin>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/record.json</uri>
</json:item>
</metadata>
<annexes><json:item><extension>jpeg</extension>
<original>true</original>
<mimetype>image/jpeg</mimetype>
<uri>https://api.istex.fr/ark:/67375/NVC-58CLR79L-G/annexes.jpeg</uri>
</json:item>
</annexes>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001436 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001436 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:09EF1A5FE6EEE42F7CC060AD8734A806E9491908
   |texte=   Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome

Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri